Unique ID issued by UMIN | UMIN000035437 |
---|---|
Receipt number | R000040370 |
Scientific Title | A multi-institutional prospective cohort study of employment after colorectal cancer surgery |
Date of disclosure of the study information | 2019/05/07 |
Last modified on | 2023/03/29 12:53:21 |
A multi-institutional prospective cohort study of employment after colorectal cancer surgery
A multi-institutional prospective cohort study of employment after colorectal cancer surgery
A multi-institutional prospective cohort study of employment after colorectal cancer surgery
A multi-institutional prospective cohort study of employment after colorectal cancer surgery
Japan |
Colorectal cancer
Gastrointestinal surgery |
Malignancy
NO
Our study aims are 1: to clarify the proportion of working patient and 2: to explore risk factors for returning to work, one year after surgery.
Others
To estimate proportion
To explore risk factors
Proportion of working patients one year after surgery
1) Time from surgery to returning to work
2) Proportion of employed patients one year after surgery
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) cStage I, II, or III colorectal cancer
2) planning curative surgery
3) employed at the time of diagnosis
4) obtained consent by the document
1) undergoing chemotherapy for other cancers
2) judged inappropriate by the examining doctor
140
1st name | Kazutaka |
Middle name | |
Last name | Obama |
Kyoto University
Gastrointestinal surgery
6068507
54, Kawahara-cho, Sakyo-ku, Kyoto
075-366-7595
kobama@kuhp.kyoto-u.ac.jp
1st name | Yusuke |
Middle name | |
Last name | Fujita |
Kyoto University
Gastrointestinal surgery
6068507
54, Kawahara-cho, Sakyo-ku, Kyoto
075-366-7595
0424.yusuke@gmail.com
Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University
The Mitsubishi foundation
Non profit foundation
Kyoto University Graduate School and Faculty of Medicine Kyoto University Hospital Ethics Committe
54, Kawahara-cho, Sakyo-ku, Kyoto
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
NO
2019 | Year | 05 | Month | 07 | Day |
Unpublished
Unpublished
Unpublished
130
The median time to return to work was 1.1 months, and the proportion of working patients at 12 months after surgery was 79%.
2023 | Year | 03 | Month | 29 | Day |
Of the 129 patients, 50 (39%) were over 65 years, 46 (36%) were female, and 62 (48%) had rectal cancer. There were 48 patients (37%) with clinical stage III CRC and 126 (98%) who received minimally invasive surgery. Six patients (5%) received preoperative radiation. However, all of these patients were also included in the group of nine patients (7%) who received preoperative chemotherapy. Stoma was created for 31 patients (24%). Postoperative overall complications were observed in 27 patients (21%). In addition, 50 patients (39%) underwent adjuvant chemotherapy. A total of 45 patients (35%) were regular employees, 43 (33%) were non-regular employees, and 40 (31%) were self-employed. Seventy-two patients (56%) worked in companies with 50 or fewer employees. Finally, most patients (89%) were willing to RTW.
One patient was excluded after enrollment as they were diagnosed with ovarian cancer, not CRC, during surgery. Accordingly, 129 patients were included in the analyses.
The questionnaire was used to follow up on 128 patients (99%) at six months and 125 patients (97%) at 12 months.
None
The time it takes patients to return to work after surgery and the proportion of working patients 12 months after surgery
Completed
2018 | Year | 02 | Month | 15 | Day |
2019 | Year | 04 | Month | 05 | Day |
2019 | Year | 06 | Month | 01 | Day |
2021 | Year | 09 | Month | 09 | Day |
2021 | Year | 10 | Month | 21 | Day |
We estimate the proportion of working patients one year after surgery. We estimate the proportion of employed patients in the same way. We estimate the time from surgery to returning to work with the Kaplan-Meier method.
We explore the influence of clinical factors and socioeconomic factors on returning to work by estimating their risk ratio and odds ratio. In particular, when we explore the effects of adjuvant chemotherapy, we focus on patients with pStageII, III.
2019 | Year | 01 | Month | 04 | Day |
2023 | Year | 03 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040370